Scotiabank began coverage on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a report issued on Friday morning, ...

Fintel reports that on March 7, 2025, Scotiabank initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Sector ...

Analysts have recently evaluated Avidity Biosciences and provided 12-month price targets. The average target is $69.0, ...

Scotiabank analyst Louise Chen initiated coverage of Avidity Biosciences (RNA) with an Outperform rating and $70 price target The firm sees a ...

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics ...

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics ...

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report)’s stock price gapped down before the market opened on Monday after Barclays lowered their price target on the stock from $63.00 to $57.00. The ...

Avidity Biosciences specializes in RNA-based therapies using Antibody-oligonucleotide conjugates to deliver drugs directly to muscle and heart cells. Learn more on RNA stock here.

Building on success across its three clinical programs, Avidity is leading in rare neuromuscular diseases with a strong balance sheet to execute on a transformational 2025 Major milestones ...

SAN DIEGO, Feb. 28, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody ...

In March, Avidity reported positive del-desiran long-term 4 mg/kg data from the MARINA-OLE™ study showing reversal of disease ...